SCHEMBL5652311

SCHEMBL5652311

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccc(Cn3ccnc3C)cc2)c1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
CDC7 O00311 3/20 0.38
DBF4 Q9UBU7 3/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
RECQL P46063 1/20 0.37
MAPK10 P53779 1/20 0.37
MAPT P10636 2/20 0.37
MAPK1 P28482 1/20 0.37
HPGD P15428 2/20 0.36
MDM2 Q00987 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651822 0.88 PDE6D (0.39) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL5652595 0.86 MAPT (0.45) ALDH1A1MEN1KMT2ACDC7DBF4
SCHEMBL5654915 0.85 MAPT (0.43) ALDH1A1MEN1KMT2APDE4APDE4B
SCHEMBL5650136 0.84 MAPT (0.51) ALDH1A1MEN1KMT2ACDC7DBF4
SCHEMBL5654426 0.83 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ATRPM8SMN1; SMN2
SCHEMBL5650867 0.83 MAPT (0.47) ALDH1A1MEN1KMT2ACDC7DBF4
SCHEMBL5652764 0.82 MAPT (0.45) ALDH1A1MEN1KMT2ACDC7DBF4
SCHEMBL5652293 0.81 MAPT (0.44) ALDH1A1MEN1KMT2ACDC7DBF4
SCHEMBL5647395 0.81 MAPT (0.50) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL5652339 0.81 MAPT (0.44) ALDH1A1MEN1KMT2ACDC7DBF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 ALDH1A1 1498/4885MEN1 4697/4885KMT2A 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.